| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18760 R79786 |
Moore (Topiramate) (Mixed indications) (Controls exposed to LTG), 2025 | Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.38 [1.08;1.75] C excluded (control group) |
120/391 481/1,976 | 601 | 391 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18761 R79790 |
Moore (Topiramate) (Mixed indications) (Controls unexposed, general pop), 2025 | Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Matched | 1.28 [1.01;1.63] | 120/391 894/3,828 | 1,014 | 391 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16756 R70384 |
Vajda (Topiramate) (Controls exposed to LTG) (Epilepsy), 2024 | Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.72 [0.09;5.75] C excluded (control group) |
1/45 10/326 | 11 | 45 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16204 R67134 |
Vajda (Topiramate) (Controls unexposed sick) (Epilepsy), 2024 | Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 10.24 [0.41;255.93] C | 1/45 0/149 | 1 | 45 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8564 R28485 |
Meador (Topiramate) (Controls exposed to Lamotrigine, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.84 [0.13;62.17] C excluded (control group) |
0/6 3/113 | 3 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8565 R28489 |
Meador (Topiramate) (Controls unexposed, disease free), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
19.18 [0.35;1060.61] C excluded (control group) |
0/6 0/106 | 0 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8566 R28493 |
Meador (Topiramate) (Controls unexposed, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.64 [0.05;149.97] C | 0/6 0/15 | 0 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8578 R28537 |
Trivedi (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
9.17 [1.91;43.94] C excluded (control group) |
5/11 4/48 | 9 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8579 R28538 |
Trivedi (Topiramate) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 38.86 [5.02;301.19] | 5/11 5/178 | 10 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8554 R28460 |
Arkilo (Topiramate), 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.87 [0.09;91.05] C | 0/2 2/24 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 4.84 [0.85;27.69] | 1,027 | 455 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Mixed indications) (Controls unexposed, general pop; 2: Topiramate) (Controls unexposed sick) (Epilepsy; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate) (Controls unexposed, sick; 5: Topiramate;
Asymetry test p-value = 0.1614 (by Egger's regression)
slope=0.0884 (0.2054); intercept=1.4108 (0.7624); t=1.8504; p=0.1614
excluded 8578, 8564, 8565, 16756, 18760